Malmö, 9 December 2025: The MedTech AI company SensoDetect AB (publ) today publishes a Q&A to give an update of ongoing projects and provide clarity. The Q&A is based on questions from investors and aim to provide a thorough overview as well as an insight into the company and the strategy forward.

• Our main focus is that our investors and the public feel confident with SensoDetect as a company. We hope that the Q&A will provide clarity and reassurance that progress is being made and that projects are advancing. If there are any additional or complementary questions, we are happy to answer them during a live Q&A next Monday, 15 December at 12.00 CET. We have scheduled the session during lunch break as we would like to give as many as possible the chance to join, says PA Hedin, CEO at SensoDetect, who also emphasizes that the company's communication will be more concise and transparent moving forward.

Q&A key highlights include:
 

• 2026 will most likely be the year when commercial revenue becomes more visible, this due to the progressing of the clinical programs, JV licensing structures being activated, AI development has a defined plan and initial license payments have been confirmed.
   
• The AI engine is currently being integrated across global pilot programs. Each BERA test generates up to 7,200 structured signal images with 256 datapoints each, enabling the AI to apply the same advanced pattern-recognition methods that have driven modern AI's explosive development. This creates a powerful foundation for improved clinical precision, scalability and future biomarker discovery. The new AI architecture enhances robustness, speed and demographic consistency, supporting high-volume screening models. Full validated performance metrics will be published following clinical and regulatory review.

• A new screening strategy where SensoDetect provides a complete method, AI platform and training is currently being rolled out. In the first stage of the roll out, this will primarily be available for private schools and private companies with a wider launch to be expected.

The Q&A can be found found here. This link to the live Q&A will be active once the event starts, on 15 December at 12.00 CET. The event will be held in English and hosted by PA Hedin and Dr Mohamed Atwa, Global Head of Clinical Research at SensoDetect.